Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise

The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas grew too quickly, partner Bruce Booth wrote in a blog post.